Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Mar 2023
The FDA has approved tropinetide (Daybue; Acadia Pharmaceuticals) to treat Rett syndrome in patients 2 years of age and older.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Study finds primary-care doctors often overlook prostate cancer risk in Black men
2.
Liver cancer survival rates reflect income disparities
3.
Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery
4.
Higher levels of HIF2α found to slow down aggressive childhood cancer
5.
Novel radiotracer identifies biomarker for triple-negative breast cancer
1.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
2.
Building Bridges between Heart and Cancer Care: A Comprehensive Guide to Cardio-Oncology Clinics
3.
The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology
4.
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial
5.
Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge